PL358188A1 - Pochodne pirolopirymidynonu, sposób ich otrzymywania oraz zastosowanie - Google Patents

Pochodne pirolopirymidynonu, sposób ich otrzymywania oraz zastosowanie

Info

Publication number
PL358188A1
PL358188A1 PL01358188A PL35818801A PL358188A1 PL 358188 A1 PL358188 A1 PL 358188A1 PL 01358188 A PL01358188 A PL 01358188A PL 35818801 A PL35818801 A PL 35818801A PL 358188 A1 PL358188 A1 PL 358188A1
Authority
PL
Poland
Prior art keywords
sub
sup
cycloalkyl
optionally substituted
fluoro atoms
Prior art date
Application number
PL01358188A
Other languages
English (en)
Other versions
PL210796B1 (pl
Inventor
Dae-Kee Kim
Ju Young Lee
Do Hyun Ryu
Nam Kyu Lee
Suk Ho Lee
Nam-Ho Kim
Jae-Sun Kim
Je Ho Ryu
Jin-Young Choi
Guang-Jin Im
Won-Son Choi
Tae Kon Kim
Hoon Cha
Original Assignee
Sk Chemicals Co, Ltd.
In2Gen Co Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Chemicals Co, Ltd., In2Gen Co Ltd. filed Critical Sk Chemicals Co, Ltd.
Publication of PL358188A1 publication Critical patent/PL358188A1/pl
Publication of PL210796B1 publication Critical patent/PL210796B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
PL358188A 2000-02-17 2001-02-15 Pochodne pirolopirymidynonu, kompozycja farmaceutyczna, sposób ich otrzymywania oraz zastosowanie PL210796B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20000007625A KR100358083B1 (ko) 2000-02-17 2000-02-17 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
PCT/KR2001/000227 WO2001060825A1 (en) 2000-02-17 2001-02-15 Pyrrolopyrimidinone derivatives, process of preparation and use

Publications (2)

Publication Number Publication Date
PL358188A1 true PL358188A1 (pl) 2004-08-09
PL210796B1 PL210796B1 (pl) 2012-03-30

Family

ID=19647449

Family Applications (1)

Application Number Title Priority Date Filing Date
PL358188A PL210796B1 (pl) 2000-02-17 2001-02-15 Pochodne pirolopirymidynonu, kompozycja farmaceutyczna, sposób ich otrzymywania oraz zastosowanie

Country Status (23)

Country Link
US (1) US6962911B2 (pl)
EP (1) EP1257553B1 (pl)
JP (1) JP4845076B2 (pl)
KR (1) KR100358083B1 (pl)
CN (1) CN1312153C (pl)
AT (1) ATE267829T1 (pl)
AU (2) AU2001236140B9 (pl)
BR (1) BRPI0108395B8 (pl)
CA (1) CA2400268C (pl)
DE (1) DE60103508T2 (pl)
DK (1) DK1257553T3 (pl)
ES (1) ES2222344T3 (pl)
HU (1) HU230344B1 (pl)
IL (2) IL151234A0 (pl)
MX (1) MXPA02007942A (pl)
NO (1) NO323553B1 (pl)
NZ (1) NZ520842A (pl)
PL (1) PL210796B1 (pl)
PT (1) PT1257553E (pl)
RU (1) RU2263676C2 (pl)
TR (1) TR200402101T4 (pl)
WO (1) WO2001060825A1 (pl)
ZA (1) ZA200206587B (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도
EP1362858A1 (en) * 2002-05-15 2003-11-19 SK Chemicals Co., Ltd. Pyrrolopyrimidinone derivates, process of preparation and use
DE10229778A1 (de) * 2002-07-03 2004-01-29 Bayer Ag Neue Verwendung von Imidazotriazinonen
FR2842809A1 (fr) * 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
CN100374441C (zh) 2003-06-06 2008-03-12 天津倍方科技发展有限公司 二氢吡咯[2，3-d]嘧啶-4-酮衍生物，其制备方法及其制药用途
TW200745106A (en) * 2005-10-03 2007-12-16 Astrazeneca Ab Chemical compounds
KR20080003599A (ko) * 2006-07-03 2008-01-08 에스케이케미칼주식회사 피롤로피리미디논 유도체의 겐티세이트 염 및 이의제조방법
US20100069632A1 (en) * 2006-07-03 2010-03-18 Sk Chemicals Co., Ltd Salts of pyrrolopyrimidinone derivatives and process for preparing the same
KR101002490B1 (ko) * 2007-06-09 2010-12-17 동아제약주식회사 유데나필을 유효성분으로 함유하는 만성 심부전증 치료용약학적 조성물
WO2011047320A2 (en) 2009-10-16 2011-04-21 Rib-X Pharmaceuticals, Inc. Antimicrobial compounds and methods of making and using the same
US9216979B2 (en) 2009-10-16 2015-12-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
KR101972992B1 (ko) 2009-10-16 2019-04-29 멜린타 서브시디어리 코프. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
JP2013523809A (ja) 2010-04-05 2013-06-17 エスケー ケミカルズ カンパニー リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
CN102372730B (zh) * 2010-08-19 2014-03-26 山东轩竹医药科技有限公司 桥环取代的磷酸二酯酶抑制剂
CN102134242B (zh) * 2011-01-21 2013-08-28 浙江大德药业集团有限公司 一种用于治疗阳痿的快速长效的化合物
TWI490220B (zh) * 2011-04-04 2015-07-01 Sk Chemicals Co Ltd 包含ｐｄｅ５抑制劑之用於減少皮膚皺紋之組成物
KR20140065378A (ko) * 2011-04-15 2014-05-29 멜린타 테라퓨틱스, 인크. 항미생물 화합물 및 그의 제조 방법과 사용 방법
JP2014526461A (ja) * 2011-09-09 2014-10-06 エスケー ケミカルズ カンパニー，リミテッド Ｐｄｅ５抑制剤を含む皮膚しわ改善用組成物
WO2014088326A1 (ko) 2012-12-04 2014-06-12 주식회사 아리바이오 포스포디에스테라제 타입 5 저해제를 포함하는 신경세포의 아폽토시스 억제용 조성물
KR20160070066A (ko) 2013-09-09 2016-06-17 멜린타 테라퓨틱스, 인크. 항균 화합물, 및 이의 제조 방법 및 이용 방법
EP3038623A4 (en) 2013-09-09 2017-04-19 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CA2979342A1 (en) 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CN104744478B (zh) * 2015-03-20 2016-08-24 中国人民解放军第二军医大学 一种防治辐射损伤的化合物、单晶及其制备方法和应用
SMT202200190T1 (it) 2015-11-16 2022-07-21 Topadur Pharma Ag Derivati del 2-fenil-3,4-diidropirrolo[2,1-f] [1,2,4]triazinone come inibitori della fosfodesterasi e loro usi
WO2017193016A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
MX2019013626A (es) 2017-05-22 2020-01-13 Topadur Pharma Ag Modo de accion dual novedoso de activadores de guanilato ciclasa solubles e inhibidores de fosfodiesterasa y usos de los mismos.
EP3833395A1 (en) * 2018-08-06 2021-06-16 Nicox S.A. Nitric oxide releasing phosphodiesterase type 5 inhibitor
BR112021009958A2 (pt) 2018-11-28 2021-08-17 Topadur Pharma Ag modo duplo de ação de ativadores de guanilato ciclase solúveis e inibidores de fosfodiesterase e seus usos
KR102271305B1 (ko) 2020-05-21 2021-06-30 주식회사 아리바이오 치매 예방 및 치료용 조성물
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
KR102900330B1 (ko) * 2020-07-16 2025-12-15 제이투에이치바이오텍 (주) 이중 억제제 화합물 및 이들의 의약 용도
CN111825593B (zh) * 2020-08-19 2023-04-07 上海成澄科技有限公司 3-氨基吡咯-2-甲酰胺类化合物的合成方法
KR102272907B1 (ko) 2020-11-05 2021-07-05 주식회사 아리바이오 치매 예방 및 치료용 조성물
KR102272910B1 (ko) 2021-01-28 2021-07-06 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR20220140960A (ko) 2021-04-12 2022-10-19 주식회사 아리바이오 당뇨병을 동반한 치매 예방 및 치료용 조성물
KR102311224B1 (ko) 2021-04-23 2021-10-13 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
KR20220146095A (ko) 2021-04-23 2022-11-01 주식회사 아리바이오 Pde5 억제제와 글루코코르티코이드 수용체 길항제 병용투여를 통한 치매 예방 및 치료용 조성물
AU2022354094A1 (en) 2021-09-29 2024-02-15 Topadur Pharma Ag Topical compositions of 2-phenyl-3,4-dihydropyrrolo[2,l-f] [1,2,4]triazinone derivatives and uses thereof
EP4486349A1 (en) 2022-03-02 2025-01-08 Topadur Pharma AG Topical compositions and uses therof
KR20230129639A (ko) 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
KR20240117491A (ko) 2023-01-25 2024-08-01 주식회사 아리바이오 포스포디에스테라제 타입 ５ 저해제를 유효성분으로 포함하는 외상 후 스트레스 장애의 예방 또는 치료용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5761734B2 (pl) * 1973-09-27 1982-12-25 Takeda Chemical Industries Ltd
JPS5761734A (en) * 1980-10-02 1982-04-14 Teijin Ltd Spun like fabric
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5236926A (en) * 1992-02-03 1993-08-17 Warner-Lambert Company 9-substituted-8-halo or -8-hydroxy-9-deazaguanines as inhibitors or PNP for pharmaceutical compositions
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
JP3713783B2 (ja) * 1995-01-20 2005-11-09 大正製薬株式会社 １Ｈ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体
RU2097394C1 (ru) * 1996-02-06 1997-11-27 Открытое акционерное общество "Акрон" Пресс-масса для изготовления древесно-стружечных плит
US6723719B1 (en) * 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
RS50011B (sr) * 1998-04-20 2008-09-29 Pfizer Inc., Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
KR100358083B1 (ko) * 2000-02-17 2002-10-25 에스케이케미칼주식회사 피롤로피리미디논 유도체와 이의 제조방법, 그리고 이의용도

Also Published As

Publication number Publication date
MXPA02007942A (es) 2004-09-10
US20030171361A1 (en) 2003-09-11
IL151234A0 (en) 2003-04-10
DK1257553T3 (da) 2004-10-04
RU2002124872A (ru) 2004-01-10
DE60103508D1 (de) 2004-07-01
HUP0300527A2 (hu) 2003-07-28
ZA200206587B (en) 2003-10-09
IL151234A (en) 2010-05-17
KR100358083B1 (ko) 2002-10-25
CN1422271A (zh) 2003-06-04
CA2400268A1 (en) 2001-08-23
AU2001236140B9 (en) 2006-08-31
PT1257553E (pt) 2004-10-29
ATE267829T1 (de) 2004-06-15
US6962911B2 (en) 2005-11-08
NZ520842A (en) 2004-04-30
JP2003523344A (ja) 2003-08-05
CA2400268C (en) 2009-08-18
BRPI0108395B8 (pt) 2021-05-25
KR20010083637A (ko) 2001-09-01
RU2263676C2 (ru) 2005-11-10
BR0108395A (pt) 2003-03-11
PL210796B1 (pl) 2012-03-30
NO323553B1 (no) 2007-06-11
JP4845076B2 (ja) 2011-12-28
NO20023823L (no) 2002-10-09
NO20023823D0 (no) 2002-08-13
BRPI0108395B1 (pt) 2017-06-06
ES2222344T3 (es) 2005-02-01
EP1257553A1 (en) 2002-11-20
AU3614001A (en) 2001-08-27
HU230344B1 (hu) 2016-02-29
TR200402101T4 (tr) 2004-10-21
HUP0300527A3 (en) 2012-10-29
AU2001236140B2 (en) 2006-01-12
WO2001060825A1 (en) 2001-08-23
DE60103508T2 (de) 2005-06-30
EP1257553B1 (en) 2004-05-26
CN1312153C (zh) 2007-04-25

Similar Documents

Publication Publication Date Title
AU3614001A (en) Pyrrolopyrimidinone derivatives, process of preparation and use
BE2018C008I2 (pl)
BG104248A (en) Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides
MY153023A (en) Tropane derivatives useful in therapy
EG24902A (en) Pyrimidine compounds and pests controlling composition containing the same
MY132129A (en) Polyarylcarboxamides useful as lipid lowering agents
DE50204803D1 (en) 4-alkylsubstituierte thienyloxy-pyrididne als herbizide
EP1288199A4 (en) INHIBITORS OF MMP-12
DK0862562T3 (da) Benzoxazepinforbindelser, fremstilling deraf og anvendelse deraf som lipidniveauformindskende midler
MXPA02004440A (es) Derivados de pirrol como inhibidores de la fosfodiesterasa vii.
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
CA2247167A1 (en) 2-hetaroylcyclohexane-1,3-diones
TW200640916A (en) (1,5-diphenyl-1H-pyrazol-3-yl)oxadiazole derivatives, their preparation and their application in therapeutics
NZ332923A (en) Distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
IL160874A0 (en) 4-imidazolin-2-one derivatives
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
NZ336091A (en) Aqueous disinfecting cleaning composition
BR0016549A (pt) Processo para a preparação de derivados de pirazolopiridazina
MY130817A (en) Herbicides
BG104037A (en) 6-pyrrolidin-2-ylpyrindine derivatives, their preparation and application in therapy
SE8605458L (sv) 4-hydroxikumaring-derivat
EP0446743A3 (en) Herbicidal sulfonylureas, process for their preparation and intermediates
ZA200203570B (en) beta-D-5-thioxylose derivatives, preparation method and therapeutic use.
WO2002051822A3 (en) Isothiazolecarboxamides as microbicides
CA2137623A1 (en) Phenyl-substituted 1,4-dihydropyridines